Compounded Tirzepatide Side Effects: The Drug, and the Vial

Most of what people call a compounded tirzepatide side effect is a tirzepatide side effect. Nausea, diarrhea, vomiting and constipation dominate the approved product's trial record, they cluster during dose escalation, and they do not change because a pharmacy mixed the vial.^[1][3] What the compounded version adds is a second, smaller category with a different cause: errors and unknowns that come from the preparation rather than the drug. Keeping the two apart is the only way to know whether what you are feeling is expected.

Where the side effect list actually comes from

There is no trial of compounded tirzepatide. The evidence everyone quotes, including the sellers, belongs to Mounjaro and Zepbound, and it was collected in the phase 3 programs that supported their approvals. In the obesity trial that carried the weight-management approval, 2,539 adults were randomized to tirzepatide or placebo for 72 weeks, with a 20-week dose-escalation period built in. The authors' summary of the safety findings was that the most common adverse events were gastrointestinal, mostly mild to moderate, and occurred primarily during that escalation.^[3]

Of everything in the trial record, that timing is the part worth carrying, because it tells you when to expect trouble. Not evenly across the year. Concentrated in the weeks after each step up.

Taken together rather than symptom by symptom, gastrointestinal adverse reactions were reported by 56 percent of patients at each of the three doses, against 30 percent on placebo.^[1] Severe ones were much rarer: 1.7, 2.5 and 3.1 percent by dose, against 1 percent on placebo.^[1] Between 4.8 and 6.7 percent of patients stopped the drug for an adverse reaction, compared with 3.4 percent on placebo, and most who stopped did so in the first few months.^[1]

The numbers are lower in the diabetes population, where the same molecule is sold as Mounjaro: nausea ran 12, 15 and 18 percent by dose against 4 percent on placebo in the pooled placebo-controlled trials.^[2] And in the head-to-head against semaglutide in type 2 diabetes, nausea on tirzepatide was 17 to 22 percent against 18 percent on semaglutide 1 mg — close enough that the class, not the particular molecule, is doing most of the work.^[4]

The serious warnings the approved label carries

These belong to the drug, which means they apply to a compounded vial containing it. The label opens with a boxed warning: in rats, tirzepatide caused dose-dependent and duration-dependent thyroid C-cell tumors, and whether that happens in humans is not determined. Two groups must not take it at all — anyone whose family or medical history includes medullary thyroid carcinoma, and anyone carrying multiple endocrine neoplasia syndrome type 2, which the label names as a contraindication in its own right.^[1]

• Severe gastrointestinal reactions, sometimes severe enough to stop treatment. Not recommended in severe gastroparesis.^[1]
• Acute kidney injury from volume depletion, mostly reported in people who became dehydrated through vomiting or diarrhea.^[1]
• Acute gallbladder disease and acute pancreatitis.^[1]
• Hypersensitivity reactions, including anaphylaxis and angioedema.^[1]
• Hypoglycemia, particularly alongside insulin or a sulfonylurea.^[1]
• Diabetic retinopathy complications in people with type 2 diabetes.^[1]
• Pulmonary aspiration under general anesthesia, or under deep sedation — tell any surgeon or anesthetist that you are taking it.^[1]

One thing this list is not is a comparison. In the type 2 diabetes head-to-head, the serious adverse event rate ran 5 to 7 percent on tirzepatide against 3 percent on semaglutide,^[4] which is a real difference inside one trial and not a general ranking of the two drugs.

Now the part that is specific to a compounded vial

Everything above would be equally true of a prescription filled at a retail pharmacy. The following four are not, and they are the reason this article exists separately from a page about Zepbound.

1. You are measuring the dose, and the concentration is not standardized

An approved tirzepatide presentation states its strength on a label FDA reviewed. Zepbound's multi-dose vials, for instance, run from 4.17 mg/mL to 25 mg/mL, each delivering four fixed 0.6 mL doses, and every one of those figures is printed in the prescribing information.^[1] A compounded vial's concentration is whatever the compounding pharmacy chose. It is not on an approved label, it is not standardized between pharmacies, and it can change when you switch supplier without the milligram number on your prescription changing at all.

FDA has reported multiple adverse events, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide, and it describes the mechanism as patients measuring and self-administering incorrect doses, with clinicians miscalculating in some cases.^[5] It separately reports adverse events that may relate to compounded semaglutide or tirzepatide prescribed at doses beyond the approved label — more per dose, more often, or escalated faster. Some were serious, and what drove people to seek medical attention was the gastrointestinal cluster: sickness, vomiting, loose stools, stomach pain and constipation.^[5]

2. There may be ingredients the trials never studied

The approved product's ingredient list is short. Besides tirzepatide, Zepbound's single-dose presentations contain water, sodium chloride and a phosphate buffer salt; the multi-dose ones add benzyl alcohol, glycerin and phenol as preservatives. No vitamin appears anywhere on it.^[1]

Compounded vials frequently carry more. In the one published survey of this market — pharmacy researchers who searched compounder websites in early 2025 and cataloged 33 distinct products, one-third of them tirzepatide — 48 percent combined the GLP-1 with cyanocobalamin, glycine, niacinamide, docusate or ondansetron. The authors' conclusion was that they found little justification for adding nutrients or docusate sodium to an injectable product.^[6] MEDLINE indexes that paper as an editorial, so treat it as a structured look at what is for sale with the authors' judgment attached, not as a measurement.

The consequence for a side effect question is precise: if your vial contains something the approved product does not, no line in the trial record describes what that ingredient does in an injectable tirzepatide preparation, in either direction. It has not been tested for benefit and it has not been tested for harm. We work through the same problem on the other molecule in why compounded semaglutide is mixed with B12.

3. Your reaction may never reach anyone who counts it

This one is invisible to the person it happens to. An outsourcing facility registered under 503B is required to report adverse events to FDA.^[7] A state-licensed 503A pharmacy that is not an outsourcing facility is not, and FDA says so explicitly, adding that adverse events from compounded versions of these drugs are therefore likely underreported.^[5] As of May 31, 2026 the agency had received 990 reports involving compounded semaglutide and more than 730 involving compounded tirzepatide, and it notes that many of them look consistent with what is already known about the approved products.^[5]

So the safety signal for a compounded product accumulates more slowly than for an approved one, from a system that does not require the reports. You can put your own report in directly through FDA's MedWatch program, and it is worth doing. Which kind of compounder made your vial is a question our pharmacy register exists to answer, and it changes whether your reaction is counted anywhere.

4. A batch problem is a possibility that an approved product mostly forecloses

Injectable GLP-1 drugs require refrigeration, and FDA has received complaints of compounded ones arriving warm or with inadequate ice, which can affect quality; its advice is not to use them.^[5] It has also documented fraudulent compounded semaglutide and tirzepatide whose labels name pharmacies that do not exist, or real pharmacies that did not make the product — including one reported adverse event, with injection site redness, swelling, pain and a lump, tied to a product labeled as compounded tirzepatide from a pharmacy that had not compounded it.^[5] An injection site reaction is on the approved label too.^[1] That is exactly why the source of the vial is worth establishing before you try to interpret the reaction.

The two columns, side by side

What to do with a symptom

1. Get care first for the serious ones. Stomach pain that will not settle, vomiting that stops you keeping fluids down, a swollen face or throat, difficulty breathing, or a lump in your neck are not things to research. They are things to call about.
2. Check the arithmetic before you change anything. Ask the pharmacy for the concentration in milligrams per milliliter, and for the dose volume in the units on your syringe. Bring both numbers to your prescriber. This is the one check that is unique to a compounded vial and it takes one phone call.
3. Ask what else is in it. If there is a second active ingredient, say so when you describe the symptom, because the person advising you cannot assume the vial contains tirzepatide alone.
4. Report it to FDA yourself through MedWatch. If a 503A pharmacy made your vial, no one else is required to.^[5]
5. Do not solve it by adjusting the dose. Escalation timing is where most of these reactions live, and changing it is a clinical decision.

If the answer to any of the first three questions is a slogan rather than a number, that is information about your seller. Our safety breakdown for compounded tirzepatide covers the regulatory side of the same problem, the ranked board records what each program discloses about its pharmacy, and the price tracker carries a dated figure for every program we follow.